Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $21.38 Average Target Price from Analysts
Shares of Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) have earned an average rating of “Moderate Buy” from the thirteen brokerages that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, six have given a buy rating and […]
31 Dec 07:56 · The Markets Daily